rupiya.io
⠋Loading...
0%
❯ Evaluating quality metrics...
Sun Pharma Inds. is a leading Indian company in the Pharmaceuticals space, listed on the NSE. The company is a key player in the Pharma — Formulations segment with a strong market position and diversified operations.
Sun Pharmaceutical Industries Ltd makes money through Core Business, Other Segments, Exports in Pharma — Formulations. Revenue quality depends on demand growth, margin discipline, balance-sheet strength, and the company's ability to defend its position within Pharma.
Create a free account to view momentum, moving averages, and delivery signals.
Upgrade to view volatility, drawdown, factor, and risk metrics.
| Metric | 1 Year | 3 Years | 5 Years | 10 Years |
|---|---|---|---|---|
| Sales | — | — | — | — |
| Profit | — | — | — | — |
| Stock Price | — | — | — | — |
| ROE | — | — | — | — |
| Period | FY25 | FY24 | FY23 | FY22 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | ₹52,041 Cr | ₹47,758 Cr | ₹43,279 Cr |
| Quarter | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | ₹11,241 Cr | ₹10,931 Cr | ₹11,941 Cr | ₹12,192 Cr | ||||||||
| Expenses | ₹8,237 Cr | ₹8,129 Cr | ₹8,609 Cr | ₹9,013 Cr | ||||||||
| Operating Profit | ₹3,004 Cr | ₹2,802 Cr | ₹3,332 Cr | ₹3,179 Cr |
| Period | FY25 | FY24 | FY23 | FY22 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Liabilities | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Equity Capital | ₹240 Cr | ₹240 Cr | ₹240 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Period | Operating | Investing | Financing | Net Cash Flow |
|---|---|---|---|---|
| FY25 | ₹14,072 Cr | ₹-5,306 Cr | ₹-7,906 Cr | ₹860 Cr |
| FY24 | ₹12,135 Cr | ₹-690 Cr | ₹-6,710 Cr | ₹4,735 Cr |
| FY23 | ₹4,959 Cr | ₹-7,944 Cr | ₹2,376 Cr | ₹-608 Cr |
| FY22 | ||||
| Mar 2015 | ||||
| Mar 2016 | ||||
| Mar 2017 |
| Ratio | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 | FY11 | FY10 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE % | 15.4% | 13.7% | 14.7% | — | — | — | — | — | — | — | — | — | — | — | — |
| ROCE % | 16.9% | 15.3% | 16.3% | — | — | — | — | — | — | — | — | — | — | — | — |
| Debt/Equity | 0.5 | 0.4 | 0.4 | — | — | — | — | — | — | — | — | — | — | — | — |
| Interest Coverage | 13.2 | 13.6 | 9.0 | — | — | — | — | — | — | — | — | — |
| Year | Type | Amount (₹) |
|---|---|---|
| FY24 | Final | ₹19.99 |
| FY23 | Final | ₹4.51 |
| FY22 | Final | ₹6.15 |
| FY21 | Final | |
| FY20 | Interim | |
| FY19 | Final |
No corporate actions recorded.
| Company | M.Cap | P/E | ROE | 1Y Return |
|---|---|---|---|---|
| Dr Reddys Laboratories Ltd | ₹1,11,310 Cr | 19.7 | +11.84% | +8.74% |
| Cipla Ltd | ₹1,15,638 Cr | 25.5 | +11.74% | -5.78% |
| Apollo Hospitals Enterprise Ltd | ₹1,16,201 Cr | 64.5 | 0.00% | +7.74% |
| Divis Laboratories Ltd | ₹1,79,486 Cr | 72.5 | 0.00% | +3.69% |
| Torrent Pharmaceuticals Ltd | ₹1,49,446 Cr | 69.7 | 0.00% | +15.25% |
Create a free account to see institutional ownership snapshots.
Create a free account to view recent director and promoter trades.
Create a free account to view recent institutional deal activity.
Create a free account to view analyst estimate summaries.
Create a free account to view ESG risk and governance summaries.
Upgrade to view issuer ratings, instruments, outlooks, and rating history.
rupiya.io is for research and education only. Metrics shown are not investment advice. Validate with SEBI-regulated disclosures before acting.
Deep-dive analysis of Sun Pharma Inds.'s competitive moat, management quality, and growth runway available with Premium.
Premium| Expenses | ₹39,460 Cr | ₹37,290 Cr | ₹34,002 Cr |
| Operating Profit | ₹12,581 Cr | ₹10,468 Cr | ₹9,277 Cr |
| OPM % | 24.2% | 21.9% | 21.4% |
| Other Income | ₹86 Cr | ₹106 Cr | ₹80 Cr |
| Depreciation | ₹2,575 Cr | ₹2,557 Cr | ₹2,530 Cr |
| Interest | ₹231 Cr | ₹238 Cr | ₹172 Cr |
| Profit Before Tax | ₹13,752 Cr | ₹11,088 Cr | ₹9,408 Cr |
| Tax | ₹2,772 Cr | ₹1,439 Cr | ₹848 Cr |
| Net Profit | ₹10,929 Cr | ₹9,576 Cr | ₹8,474 Cr |
| EPS (₹) | 45.6 | 39.9 | 35.3 |
| Dividend Payout % | 0% | 0% | 0% |
Register free to see 13 more years.
| OPM % | 27.0% | 26.0% | 28.0% | 26.0% |
| Depreciation | ₹660 Cr | ₹672 Cr | ₹651 Cr | ₹633 Cr |
| Interest | ₹46 Cr | ₹93 Cr | ₹81 Cr | ₹49 Cr |
| Net Profit | ₹2,181 Cr | ₹1,983 Cr | ₹2,006 Cr | ₹2,385 Cr |
| EPS (₹) | 9.0 | 8.3 | 8.4 | 9.9 |
Register free to see 8 more quarters.
| Reserves | ₹57,862 Cr | ₹50,155 Cr | ₹43,610 Cr |
| Borrowings | ₹2,362 Cr | ₹3,274 Cr | ₹6,886 Cr |
| Other Liabilities | ₹17,252 Cr | ₹15,100 Cr | ₹14,542 Cr |
| Total Liabilities | ₹19,615 Cr | ₹18,374 Cr | ₹21,428 Cr |
| Assets |
| Fixed Assets | ₹11,487 Cr | ₹11,489 Cr | ₹11,484 Cr |
| Investments | ₹449 Cr | ₹443 Cr | ₹384 Cr |
| Receivables | ₹13,046 Cr | ₹11,249 Cr | ₹11,439 Cr |
| Inventory | ₹10,243 Cr | ₹9,868 Cr | ₹10,513 Cr |
| Cash & Equivalents | ₹10,269 Cr | ₹9,286 Cr | ₹4,624 Cr |
| Other Assets | ₹46,607 Cr | ₹43,165 Cr | ₹42,301 Cr |
| Total Assets | ₹92,101 Cr | ₹85,500 Cr | ₹80,744 Cr |
Register free to see 13 more years.
| Mar 2018 |
| Mar 2019 |
| Mar 2020 |
| Mar 2021 |
| Mar 2022 |
| Mar 2023 |
| Mar 2024 |
| Mar 2025 |
Register free to see 13 more years.
| — |
| — |
| — |
| Current Ratio | 1.4 | 1.7 | 1.6 | — | — | — | — | — | — | — | — | — | — | — | — |
| Quick Ratio | 1.3 | 1.3 | 1.3 | — | — | — | — | — | — | — | — | — | — | — | — |
| OPM % | 15.7% | 12.9% | 15.4% | — | — | — | — | — | — | — | — | — | — | — | — |
| NPM % | 9.4% | 7.8% | 9.2% | — | — | — | — | — | — | — | — | — | — | — | — |
| EV/EBITDA | 14.7 | 14.8 | 12.1 | — | — | — | — | — | — | — | — | — | — | — | — |
| PEG Ratio | 1.6 | 1.3 | 1.7 | — | — | — | — | — | — | — | — | — | — | — | — |
| Asset Turnover | 1.4 | 1.1 | 0.9 | — | — | — | — | — | — | — | — | — | — | — | — |
| Inventory Turnover | 7.9 | 11.0 | 7.2 | — | — | — | — | — | — | — | — | — | — | — | — |
Register free to see 12 more years of ratio trends.